Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
US-2016068497-A1 · Mar 10, 2016 · US
Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
US10118907B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10118907-B2 |
| Application number | US-201715435826-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 17, 2017 |
| Priority date | Jun 20, 2011 |
| Publication date | Nov 6, 2018 |
| Grant date | Nov 6, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
First claim
Opening claim text (preview).
What is claimed: 1. A method of treating schizophrenia, schizophreniform disorder, or schizoaffective disorder in a subject in need thereof comprising administration of an effective amount of the hydrochloride salt of a deuterium enriched compound of formula Y: wherein, R 1 -R 10 are independently hydrogen or deuterium, wherein at least two of R 1 -R 10 are deuterium. 2. The method of claim 1 , further comprising administration of at least one neuroleptic agent. 3. The method of claim 2 , wherein the neuroleptic agent is selected from sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant. 4. The method of claim 1 , wherein the compound is 5. The method of claim 1 , wherein the compound is 6. The method of claim 1 , wherein the compound is 7. The method of claim 1 , wherein the compound is 8. The method of claim 1 , wherein the compound is 9. The method of claim 1 , wherein the compound is
Assignees
Inventors
Classifications
Antidepressants · CPC title
Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Drugs for disorders of the nervous system · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10118907B2 cover?
- The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising admini…
- Who is the assignee on this patent?
- H Lundbeck As
- What technology area does this patent fall under?
- Primary CPC classification C07D295/073. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).